Replies to post #161461 on Anavex Life Sciences Corp (AVXL)

[tradeherpete]

The only thing I don't like about the study is that they have MMSE 20-28 as inclusion criteria (based on HH's slide at AAIC) and many MMSE 27 and 28 (MCI not mild AD) patients would not be expected to decline over 48 weeks. This potentially weakens a treatment effect if the numbers of these patients are too high.

Kind of out of my league here but do we know all the biomarkers that are being used in the /3? Is it possible the 27-28 could be predicted to decline as early AD patients? Maybe this is also part of learning about early decline with MCI types?

And if it turns out some of those end up in the placebo group and decline as expected wouldn’t that support including them?